Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Victorian Melanoma Service, Alfred Health, Melbourne, Victoria, Australia.
Br J Haematol. 2022 May;197(3):320-325. doi: 10.1111/bjh.18090. Epub 2022 Mar 14.
With new, effective treatments for chronic lymphocytic leukaemia (CLL) the impact of second malignancies is increasingly important. We performed a retrospective case-controlled study examining the effect of CLL and its treatment on melanoma-specific survival and recurrence. A total of 56 patients with melanoma with CLL were matched 1:1 to patients without CLL for age, date of diagnosis, gender and melanoma tumour, node, metastasis (TNM) stage. Multivariate analysis found CLL was associated with significantly worse melanoma-specific mortality (hazard ratio [HR] 2.46, 95% confidence interval [CI] 1.27-4.74, p = 0.007) and recurrence (HR 3.44, 95% CI 1.79-6.63, p < 0.001). Patients with CLL had poor immunotherapy tolerance and prior CLL treatment was not associated with melanoma outcomes.
随着慢性淋巴细胞白血病（CLL）新的有效治疗方法的出现，第二恶性肿瘤的影响变得越来越重要。我们进行了一项回顾性病例对照研究，研究了 CLL 及其治疗对黑色素瘤特异性生存和复发的影响。共纳入 56 例合并 CLL 的黑色素瘤患者，按年龄、诊断日期、性别和黑色素瘤肿瘤、淋巴结、转移（TNM）分期与无 CLL 的患者进行 1:1 匹配。多因素分析发现 CLL 与黑色素瘤特异性死亡率显著相关（风险比 [HR] 2.46，95%置信区间 [CI] 1.27-4.74，p=0.007）和复发（HR 3.44，95%CI 1.79-6.63，p<0.001）。患有 CLL 的患者免疫治疗耐受性差，且既往 CLL 治疗与黑色素瘤结局无关。
